Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ConsumerLab iron tests finish up strong

This article was originally published in The Tan Sheet

Executive Summary

All 15 iron supplements evaluated by online testing firm were found to contain iron amounts listed on the label with acceptable lead levels and disintegration qualities necessary for absorption, ConsumerLab announces July 26. Four products under the Sundown Benefits, Puritan's Pride and Vitamin World brands were submitted voluntarily for testing, while ConsumerLab.com selected the 11 other products for certification. Results of the sample were an improvement over a 2001 test in which 17 of 19 iron supplements passed (1"The Tan Sheet" Oct. 8, 2001, In Brief)...

You may also be interested in...



ConsumerLab.com

Seventeen of 19 iron supplements pass tests for label accuracy, disintegration rate and lead levels, online firm announces Oct. 3. Passing products included SmithKline Beecham's Feosol Ferrous Sulfate (65 mg), Novartis' Slow Fe Slow Release Iron (50 mg) and Twinlab's eponymous Iron Caps (18 mg). One failing product, which was marketed specifically to women, "contained lead at a level in excess of .5 mcg per daily serving," while another contained only 19.7 mg of claimed 27 mg on the label. ConsumerLab expects to release nutrition bar results later this month

Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 

Topics

UsernamePublicRestriction

Register

PS097090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel